There are a couple of big ones for USD/JPY to take note of, as highlighted in bold.However, with it being a US holiday, there might not be much interest considering the price levels and lack of meaning action so far on the day. Both the dollar and yen are mildly softer as risk tones are holding u
Archiv für den Monat: Januar 2022
China’s strong yuan despite mixed data
China published mixed economic data noting a slowdown in a year-over-year comparison, but some of the data exceeded expectations. The Chinese renminbi has been on the offensive against the US dollar for the past week, bringing USDCNH back to test the lows of the past six months. The economy gre
Tianjin reports biggest daily rise of latest COVID-19 outbreak
That is up from 33 cases the day before. But while travel curbs – especially to Beijing – have been imposed, the city of 14 million is managing to avoid a total lockdown for the time being. That said, there are plenty of road closures and public transport limitations with 64 of the city’s 87 bus ser
China president Xi says fully confident in country’s economic development
Overall momentum of China’s economy is soundChina will continue with reform and opening upWorld economy still faces constraintsThe world has found itself in a new period of turbulence and transformationCountries should strengthen economic policy coordinationThose are rather general remarks but they
UK reportedly could review COVID measures some time this week or early next week
The Reuters report says that this in part efforts to move attention away from the events in Downing Street as of late, as Boris Johnson looks to reset his agenda after coming under fire over the party he attended during lockdown in 2020.The removal of „Plan B“ would appease many in the Tory party, s
[東証]改善報告書の徴求及び公表措置：（株）メタリアル
[東証]制限値幅の拡大：1銘柄
[OSE]国債先物における受渡適格銘柄及び交換比率一覧表の更新
Dax aktuell: Dax bleibt unter der 16.000-Punkte-Marke – Ausverkauf von Impfstoffherstellern lässt Abflauen der Pandemie erwarten
Die Anlegerstimmung signalisiert eindeutige Warnsignale: Der nächste Rücksetzer am deutschen Aktienmarkt hat das Potenzial für eine größere Korrektur.Patentfreie Arzneimittel: Cheplapharm kündigt Börsengang an
Cheplapharma will im Februar an die Börse. Damit steht der Frankfurter Börse der erste Börsengang des Jahres bevor – und der könnte bis zu zehn Milliarden Euro schwer werden.